ELIZABETH GOACHER: Open Payments
NPI 1841373008 · DURHAM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$14,888 in 37 payments from 7 companies in 2025. Trend: 2023 $5,121 · 2024 $9,450 · 2025 $14,888
Consulting: $8,310Speaker / faculty: $3,320Travel & lodging: $2,156Food & beverage: $1,102
| Company | Payments | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 12 | $4,799 |
| Gilead Sciences, Inc. | 12 | $4,010 |
| GlaxoSmithKline, LLC. | 4 | $3,300 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $1,364 |
| Mirum Pharmaceuticals, Inc. | 2 | $1,294 |
| Madrigal Pharmaceuticals | 1 | $103 |
| ABBVIE INC. | 1 | $18 |
Products named: IQIRVO, Livdelzi, Livmarli, TRULANCE, XIFAXAN, REZDIFFRA, MAVYRET, Bylvay.
Industry payments across NC — which companies pay providers there.
